Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study is aimed to study the pharmacokinetic characteristics(e.g. AUC, Cmax, Tmax) of Ypeginterferon alfa-2a and interferon biomarkers(e.g. 2,5-OAS, neopterin) after single dose at different levels.
Phase:
Phase 1
Details
Lead Sponsor:
Xiamen Amoytop Biotech Co., Ltd.
Treatments:
Interferon-alpha
Peginterferon alfa-2a